The Centers for Medicare & Medicaid Services May 16 released a final rule with the intent of lowering drug prices for beneficiaries enrolled in Medicare Advantage and Part D programs. The rule finalizes language aimed at increasing transparency for Part D beneficiaries, as well as the option for MA plans to utilize step therapy for Part B drugs.
 

Related News Articles

Headline
The Senate Judiciary Committee Subcommittee on Competition Policy, Antitrust, and Consumer Rights yesterday held a hearing on surging drug prices and…
Headline
The AHA July 2 expressed support for the Drug-Price Transparency for Consumers Act of 2021 (S.2304).    “America’s hospitals and health systems are…
Headline
The AHA today expressed support for the Improving Seniors’ Timely Access to Care Act of 2021 (H.R. 3173), bipartisan legislation that would establish…
Headline
The AHA today urged the Centers for Medicare & Medicaid Services to use its oversight authority for Medicare Advantage, Medicaid managed care, Children’s…
Headline
The Centers for Medicare & Medicaid Services today finalized additional provisions for the Medicare Advantage and Part D prescription drug programs…
Headline
The Centers for Medicare & Medicaid Services yesterday released a request for applications from Medicare Advantage and prescription drug plans to…